Disease activity during the premenopausal and postmenopausal periods in women with systemic lupus erythematosus

American Journal of Medicine

Volumn 111, Issue 6, 2001, Pages 464-468

  Sánchez Guerrero, Jorge ^a   Villegas, Armando ^a   Mendoza Fuentes, Angélica ^a   Romero Díaz, Juanita ^a   Moreno Coutiño, Gabriela ^a   Cravioto, Carmen ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; DANAZOL; ESTROGEN; GESTAGEN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HEALTH SERVICE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MORBIDITY; ONSET AGE; OVARY DISEASE; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTECTION; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; CHLOROQUINE; COHORT STUDIES; DISEASE PROGRESSION; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEDICAL RECORDS; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; POSTMENOPAUSE; PREDNISONE; PREMENOPAUSE; RETROSPECTIVE STUDIES;

EID: 0035886322     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(01)00885-3     Document Type: Article

References (38)

1. Sex effects in systemic lupus erythematosus: A clue to pathogenesis
2. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus
3. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus
4. Effect of pregnancy on course of systemic lupus erythematosus
5. Lupus erythematosus and ovarian function: Observations on a possible relationship with a report of 6 cases
6. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus
7. Oestrogen-induced systemic lupus erythematosus
8. Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE)
9. Hormonal replacement therapy in systemic lupus erythematosus
10. Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus
11. Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies and glomerulonephritis in NZB/NZW F1 mice
12. Delayed androgen treatment prolongs survival in murine lupus
13. Androgenic hormones modulate autoantibody responses and improve survival in murine lupus
14. Hormonal modulation in systemic lupus erythematosus. Preliminary clinical and hormonal results with cyproterone acetate
15. Onset of symptoms of rheumatoid arthritis in relation to age, sex, and menopausal transition
16. Sex hormones and Sjogren's syndrome
17. Ovarian failure and flares of systemic lupus erythematosus
18. Systemic lupus erythematosus
19. Research on the Menopause in the 1990s
20. The International Menopause Society menopause-related terminology definitions
21. The 1982 revised criteria for the classification of systemic lupus erythematosus
22. Derivation of the SLEDAI. A disease activity index for lupus patients
23. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study
24. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices
25. The menopause
26. The menopausal transition: Analysis of LH, FSH, estradiol and progesterone concentrations during menstrual cycles of older women
27. Steroid and gonadotropin levels in women during the peri-menopausal years
28. A prospective long-term study of women from pre-menopause to post-menopause: Changing profiles of gonadotropins, oestrogens, and androgens
29. Endometrium and plasma hormone profile in the peri-menopause to post-menopause
30. Longitudinal studies on the phenomenon of postmenopausal estrogen production
31. Correlation between urinary testosterone or estrogen excretion levels and interstitial cell-stimulating hormone concentrations in normal postmenopausal women
32. Systemic lupus erythematosus. II. Observations on the occurrence of exacerbations in the disease course: Dutch experience with 110 patients studied prospectively
33. Reliability of recall of drug usage and other health-related information
34. Problems and proposals for interview data in epidemiological research
35. Variations in reporting of menstrual histories
36. Reproducibility and validity of self-reported menopausal status in a prospective cohort study
37. Validity of retrospective disease activity assessment in systemic lupus erythematosus
38. Assessment of systemic lupus erythematosus disease activity by medical record review compared with direct standardized evaluation